In a report released today, Sean Lee CFA from H.C. Wainwright reiterated a Buy rating on Cytosorbents (CTSO – Research Report), with a price target of $9.00. The company's shares closed last Tuesday at $2.18, close to its 52-week low of $1.89. According to TipRanks.com, CFA is ranked 0 out of 5 stars with an average return of -14.8% and a 19.0% success rate. CFA covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, CASI Pharmaceuticals, and Virios Therapeutics. Currently, the analyst consensus on Cytosorbents is a Strong Buy with an average price target of $9.25, which is a 285.4% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-cytosorbents-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more CytoSorbents Charts.
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more CytoSorbents Charts.